| Unique ID issued by UMIN | UMIN000063676 |
|---|---|
| Receipt number | R000072877 |
| Scientific Title | Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment |
| Date of disclosure of the study information | 2026/11/20 |
| Last modified on | 2026/11/18 12:37:33 |
Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment
NA
Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment
NA
| Japan |
Non-Muscle-Invasive Bladder Cancer
| Urology |
Malignancy
NO
To quantify patient preferences for the efficacy, safety, and administration attributes of bladder-sparing therapies for NMIBC.
Others
Patient preferences (relative preference weights for treatment attributes of bladder-sparing therapies)
Others
Not applicable
A set of relative preference weights and 95% confidence intervals for all attribute levels included in the DCE survey instrument.
Secondary: Preference weights for the prespecified Priority Enrollment Group (*1), subject to analytical feasibility criteria prespecified in the SAP; conditional relative importance of each attribute; MAR/MAB; and predicted-choice probabilities.
*1. A clinically relevant, prespecified subgroup reflecting the post-BCG treatment decision context. Participants must meet both of the following participant-reported criteria: (A) information they report having received from a physician supporting high-risk NMIBC; and (B) information they report having received from a physician supporting disease persistence or recurrence following BCG treatment, insufficient BCG response, medical unsuitability of further BCG, including BCG intolerance, treatment-limiting toxicity, or another medical reason, or insufficient expected clinical benefit of further BCG, or the need to consider treatment modification. This is an operational study classification based on participant-reported information and is not equivalent to a medically confirmed diagnosis or regulatory classification of BCG-unresponsive NMIBC.
Exploratory: Preference heterogeneity by patient background factors (subgroup analysis); latent class analysis; descriptive preferences for bladder-sparing therapies relative to RC based on direct elicitation.
Observational
| 18 | years-old | <= |
| Not applicable |
Male and Female
1)Aged 18 years or older at the time of providing informed consent.
2)Is able to understand the study information, provide informed consent personally, and complete the applicable interview or survey independently without a proxy respondent.
3)Resident of Japan
4)Self-reported diagnosis of NMIBC
5)Has undergone TURBT
6)Has previously received BCG intravesical treatment
1) Has undergone radical cystectomy.
2) Has previously received or is currently receiving a novel bladder-sparing treatment for NMIBC (see definition below).
3) Has made a final decision to receive a specific novel bladder-sparing treatment for NMIBC, regardless of whether the treatment initiation, administration, or procedure has already been scheduled.
For the purpose of these criteria, a novel bladder-sparing treatment refers to a treatment given after BCG treatment to preserve the bladder, other than intravesical BCG therapy and conventional intravesical chemotherapy (including immediate postoperative instillation), for example, intravesical gene therapy or an intravesical drug-delivery system. Unapproved treatments and treatments given in clinical trials or clinical research are also included. Receiving information about, considering, or being recommended a treatment without having made a final decision, and prior TURBT alone, are not exclusionary.
215
| 1st name | Atsushi |
| Middle name | |
| Last name | Nakano |
Ferring Pharmaceuticals Co., Ltd.
Medical Affairs
105-0001
10F The Okura Prestige Tower, 2-10-4 Toranomon, Minato-ku, Tokyo 105-0001, Japan
03-5544-9237
Atsushi.Nakano@ferring.com
| 1st name | Takako |
| Middle name | |
| Last name | Yuki |
3H Medi Solution Inc.
Insight Solution Promotion Office
171-0022
1-13-23 Minami-Ikebukuro, Toshima-ku, Tokyo
03-5953-2108
research_info_or@3h-ms.co.jp
Ferring Pharmaceuticals Co., Ltd.
Ferring Pharmaceuticals Co., Ltd.
Profit organization
Japan
Japan Conference of Clinical Research
1-13-23 Minami-Ikebukuro, Toshima-ku, Tokyo 171-0022, Japan
03-6868-7022
jccr-info@jccr.jp
NO
| 2026 | Year | 11 | Month | 20 | Day |
Unpublished
Preinitiation
| 2026 | Year | 11 | Month | 04 | Day |
| 2026 | Year | 11 | Month | 19 | Day |
| 2026 | Year | 11 | Month | 24 | Day |
| 2027 | Year | 09 | Month | 06 | Day |
Protocol number EG-26-81
This is a non-interventional, cross-sectional, web-based survey using a discrete-choice experiment (DCE) in patients with NMIBC and a history of intravesical BCG therapy. Treatment attributes of bladder-sparing therapies related to efficacy, safety, and administration will be evaluated, and patients' relative preference weights for each attribute level will be estimated using a random-parameters logit model. The survey instrument will be finalized through formative qualitative interviews (approx. 10 participants) and a pretest (approx. 5 participants), followed by the main survey (approx. 200 participants).
| 2026 | Year | 11 | Month | 18 | Day |
| 2026 | Year | 11 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072877